Singapore’s Dx Assay Pushing Fee-for-service Model In Companion Diagnostics
This article was originally published in PharmAsia News
Executive Summary
Dx assays Pte. Ltd. says its fee-for-service business model makes it a unique provider of companion diagnostics in a market set to boom globally as U.S. FDA and other regulators push for drug firms to develop diagnostics alongside drugs.
You may also be interested in...
FDA Releases Companion Dx Guidance Broad In Scope, Limited In Detail
FDA released long-awaited draft guidance on the development of drugs with companion diagnostics July 12, but the 12-page document’s concise nature left some in the industry longing for more insight.
As Asia Gets Richer, Singapore's EDB Turns Investments To Tech-enabled, Remote Monitoring Start-Ups
SINGAPORE - The Singaporean government's leading investments arm, EDB Investments, is increasingly betting on small-sized companies that leverage advanced communication technologies like mobile phones or remote monitoring to develop healthcare solutions
Dx Assays Opens R&D Lab As Singapore’s First Developer Of Molecular Diagnostic Assays
PERTH, Australia - Dx Assays, Singapore's first commercial developer of molecular diagnostic assays, opened its new R&D center in Singapore Sept. 8